| __timestamp | Exelixis, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 22223073 |
| Thursday, January 1, 2015 | 96351000 | 6966842 |
| Friday, January 1, 2016 | 95967000 | 9000499 |
| Sunday, January 1, 2017 | 112171000 | 13741186 |
| Monday, January 1, 2018 | 182257000 | 19040000 |
| Tuesday, January 1, 2019 | 336964000 | 23559000 |
| Wednesday, January 1, 2020 | 547851000 | 31931000 |
| Friday, January 1, 2021 | 693716000 | 44981000 |
| Saturday, January 1, 2022 | 891813000 | 54234000 |
| Sunday, January 1, 2023 | 1044071000 | 63806000 |
| Monday, January 1, 2024 | 910408000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
Exelixis, Inc. has shown a remarkable upward trend in R&D expenses, increasing by over 450% from 2014 to 2023. This surge underscores their aggressive pursuit of new therapies and treatments. In contrast, Viking Therapeutics, Inc. has maintained a more conservative growth in R&D spending, with a 187% increase over the same period.
This divergence highlights the strategic differences between the two companies. While Exelixis focuses on rapid expansion and innovation, Viking Therapeutics adopts a more measured approach, potentially reflecting different risk appetites and market strategies. As the biotech landscape evolves, these spending patterns may offer insights into future breakthroughs and market positioning.
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Comparing Innovation Spending: Amgen Inc. and Exelixis, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Viking Therapeutics, Inc.
Analyzing R&D Budgets: Genmab A/S vs Viking Therapeutics, Inc.
Research and Development: Comparing Key Metrics for BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Blueprint Medicines Corporation vs Viking Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for TG Therapeutics, Inc. and Viking Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Viking Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.